# Can-Fite BioPharma

Source: https://onco.cc/companies/can-fite/  
OnCo record `can-fite` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Can-Fite is an Israeli company developing adenosine A3 receptor agonists; namodenoson is in phase 3 as a second-line treatment for liver cancer in patients with poor liver function.

## Summary

Can-Fite BioPharma, founded in 1994 and based in Petah Tikva, Israel, develops small molecules that act on the adenosine A3 receptor, which is overexpressed in tumour and inflamed cells. Namodenoson is in a phase 3 trial in hepatocellular carcinoma with Child-Pugh B liver function, a group with few options, and piclidenoson is tested in psoriasis. Its trials are registered on ClinicalTrials.gov under Can-Fite as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Can-Fite BioPharma Ltd; Can Fite Biopharma
- Tags: ctgov-sponsor
- HQ: Petah Tikva
- Type: biotech
- Website: https://www.canfite.com

## Sources

- Official website: https://www.canfite.com
- ClinicalTrials.gov: trials led by Can-Fite BioPharma Ltd: https://clinicaltrials.gov/search?lead=Can-Fite%20BioPharma%20Ltd
- Wikidata: https://www.wikidata.org/wiki/Q96482303

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/can-fite.json